Document Type
Article
Publication Title
Journal of the Society for Cardiovascular Angiography & Interventions
Abstract
BACKGROUND: Mechanical thrombectomy has become a first-line adjunctive therapy for anticoagulation in patients with acute intermediate-risk pulmonary embolism (PE). This prospective study evaluated the safety and efficacy of percutaneous mechanical aspiration thrombectomy with autologous blood reinfusion using the next-generation AVENTUS Thrombectomy System (Inquis Medical) in subjects with acute intermediate-risk PE.
METHODS: Subjects with acute intermediate-risk PE with symptoms ≤14 days were enrolled in this prospective, multicenter, single-arm study. Primary efficacy (defined as the change in the right ventricle to left ventricle [RV/LV] ratio from baseline) and safety defined as a composite rate of device-related major adverse events were both assessed at 48 hours postprocedure. Six-minute walk distance and quality of life were assessed at 30 days.
RESULTS: A total of 120 subjects were enrolled at 22 US sites. As compared to the baseline, the 48-hour RV/LV diameter ratio dropped significantly (0.47 ± 0.36;
CONCLUSIONS: This study confirms that thrombectomy and autologous blood reinfusion with the AVENTUS Thrombectomy System is a safe and effective primary treatment option in patients with acute intermediate-risk PE to improve RV function and reduce clot burden with minimal blood loss.
First Page
103661
Last Page
103661
DOI
10.1016/j.jscai.2025.103661
Publication Date
7-1-2025
Recommended Citation
Sabri S, Horr S, Stegman B, Jaber WA, Jolly MA, Huff CM, O'Connor D, Younes A, Tabori NE, Monteleone PP, Kolluri R, Shishehbor MH, Li J; AVENTUS Trial Investigators. Novel Aspiration Thrombectomy and Blood Reinfusion System for Acute Intermediate-Risk Pulmonary Embolism: AVENTUS Trial Results. J Soc Cardiovasc Angiogr Interv. 2025 May 2;4(7):103661. doi: 10.1016/j.jscai.2025.103661. PMID: 40933114; PMCID: PMC12418419.